GeneDx (WGS) Expected to Post Quarterly Earnings on Monday

Posted by Brian Himes on Jul 27th, 2026

GeneDx (NASDAQ:WGS – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect GeneDx to post earnings of ($0.19) per share and revenue of $111.0090 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

GeneDx (NASDAQ:WGS – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same period last year, the business earned ($0.23) EPS. On average, analysts expect GeneDx to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

GeneDx Stock Performance

Shares of NASDAQ WGS opened at $59.10 on Monday. The firm has a 50 day moving average of $58.75 and a 200 day moving average of $72.02. The firm has a market capitalization of $1.75 billion, a price-to-earnings ratio of -22.05 and a beta of 1.90. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 12-month low of $32.21 and a 12-month high of $170.87.

Wall Street Analyst Weigh In

WGS has been the topic of several research analyst reports. Zacks Research downgraded GeneDx from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Wall Street Zen lowered shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Finally, TD Cowen reissued a “buy” rating on shares of GeneDx in a research note on Wednesday, July 15th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $87.43.

View Our Latest Analysis on WGS

Insider Activity

In other GeneDx news, Director Casdin Capital, Llc acquired 185,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was bought at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the purchase, the director owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. The trade was a 5.81% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Keith A. Meister purchased 533,758 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was purchased at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the purchase, the director owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 2,256,420 shares of company stock valued at $93,144,340 and sold 21,699 shares valued at $1,295,646. 25.17% of the stock is owned by insiders.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently modified their holdings of WGS. Royal Bank of Canada raised its holdings in shares of GeneDx by 30.2% in the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares during the period. NewEdge Advisors LLC grew its position in GeneDx by 270,700.0% in the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after acquiring an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in GeneDx by 67.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after acquiring an additional 11,375 shares in the last quarter. Finally, Cetera Investment Advisers acquired a new position in GeneDx in the 2nd quarter valued at about $249,000. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx News Roundup

Here are the key news stories impacting GeneDx this week:

Neutral Sentiment: Multiple law firms reiterated that a securities class action has been filed against GeneDx and certain executives, with the case centered on alleged misstatements about the Fabric Genomics acquisition and related synergies. Article: WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
Negative Sentiment: Several firms highlighted that investors have until August 3, 2026 to seek lead-plaintiff status, keeping the lawsuit in focus and potentially increasing overhang on the stock. Article: WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Negative Sentiment: Attorney promotions and investor alerts also pointed to the sharp stock selloff after GeneDx’s May earnings update, which disclosed a large impairment charge and weaker guidance, reinforcing concerns about prior disclosures and fundamentals. Article: Lost Money on GeneDx Holdings Corp. (WGS)? Join Class Action Suit Seeking Recovery – Contact SueWallSt

GeneDx Company Profile

(Get Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.